A major international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for ...

A drug used to treat type 2 diabetes may also be used to treat prostate cancer. The corresponding study was published in Molecular Cancer. "This is a significant discovery. For the first time, we have ...

A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have ...

TUPELO — Some avid watchers of football broadcasts have no doubt become aware of a drug called Pluvicto. That’s because commercials touting the relatively new drug were meant to target a large ...

UCL-led trial shows adding niraparib to standard therapy reduces tumour growth risk in men with advanced prostate cancer by ...

* A type 2 diabetes drug, pioglitazone, may reduce the risk of prostate cancer relapse by targeting the PPAR (and) #947; protein * Prostate cancer patients with diabetes on PPAR (and) #947; drugs had ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

Diabetes medications known as GLP-1 receptor agonists (GLP-1RAs), widely prescribed for type 2 diabetes and weight loss, have complex and varied effects on cancer risk that depend on cancer type and ...

The researchers enrolled 92 men with recurring prostate cancer into the trial. Half received radiation alone, while the other ...

MILAN, Italy — In patients with prostate cancer and cardiovascular disease, degarelix (Firmagon, Ferring Pharmaceuticals) is associated with fewer serious adverse events and less all-cause death ...

GLP-1 receptor agonists (RAs) were associated with a 17% lower overall cancer risk in adults with obesity or overweight, with particularly reduced risks for endometrial, ovarian, and meningioma ...